FREE SHIPPING on orders over $60 Details

Latest Newsflash

New Brain Imaging Technology Provides Insights Into Alzheimer’s

March 17, 2010

One of the hallmarks of Alzheimer's disease is the deposit of amyloid beta protein in clumps or plaques within the brain, measurable with PET scans that use a chemical marker or radiotracer called 11C-PIB. The emergence of multiple new brain imaging technologies and the combined application of these new approaches is helping to create new insights into aging and Alzheimer's disease. Recent studies suggest that a form of the amyloid beta protein that is soluble rather than the form that is deposited in plaques (thought to injure and perhaps cause the death of nerve cells) mediates most of the destructive impact of this protein. In a new study published in the Elsevier journal Biological Psychiatry, researchers have related the findings emerging from PET-PIB imaging to changes in the function of brain circuits. Dr. Yvette Sheline, professor of psychiatry and radiology at Washington University and lead author of the study, and colleagues examined Alzheimer's disease patients and cognitively normal, healthy individuals who were then divided into those with or without brain amyloid plaques. Using functional connectivity brain mapping, they found that amyloid plaques are present in the brains of people with Alzheimer's disease as well as some healthy elderly people who do not show behavioral evidence of Alzheimer's. However, they found that the healthy participants with brain amyloid deposits were associated with compromised connections between important brain regions involved in learning and memory even though their memory functions were not markedly impaired. Similar disruptions in brain connections were found in individuals with Alzheimer's disease. According to Dr. Sheline, "This indicates that Alzheimer's disease likely begins quietly, clinically undetected, but still slowly eroding brain networks." These findings further underscore the importance of being able to identify individuals at risk for developing Alzheimer's disease and will aid researchers as they continue to work to understand the disruption in brain functioning associated with Alzheimer's disease. "This elegant study illustrates that amyloid plaques are only a component of the disease process in Alzheimer's disease, in that that there are many people who have the plaques but not the disease. These data raise a number of important questions," commented Dr. John Krystal, editor of Biological Psychiatry. "What is missing from the disease process or what protective factors are present among people who have amyloid deposition in plaques but who appear to be without Alzheimer's disease? If the amyloid plaques were eliminated in the healthy elderly, would their brain circuitry function normalize?" These questions are important and timely as a number of approaches for reducing brain amyloid beta protein levels are currently being tested, including antibodies that might bind to and promote the clearance of amyloid beta protein as well as drugs that inhibit amyloid beta protein synthesis. If amyloid beta protein is only part of the biology of Alzheimer's disease, it may be difficult to predict the extent to which these novel treatments might work.